|
|
|
|
Illnesses Other Than Depression Show Stronger Link to Suicide
2009 American Psychiatric Association Joan Arehart-Treichel Depression prompts people to think about suicideanxiety, impulsivity, or substances can prompt them to act upon that impulse.Other factors that propel them from thought to action...
|
|
|
Lundbeck Presents Positive Results For Depressive Disorder Phase II Study
Study compared efficacy of three doses of Lu AA24530, 5mg, 10mg and 20 mg, to that of placebo Related News Business comprises a portfolio of 13 branded pharmaceuticals ...GSKs Irish combination patent for Seretide termed invalid ...
|
|
|
Sepracor Provides Update On Clinical Trials For SEP-225289, Lunesta
did not meet the primary efficacy endpoint, but Lunesta has been proven to be safe and well tolerated Sepracor has completed the analysis and validation of the preliminary results of a phase II, 514-patient study.It evaluated the efficacy...
|
|
|
Sepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA Pediatrics
Sepracor Inc.(Nasdaq: SEPR) today announced that it has completed the analysis and validation of the preliminary results of a Phase II, 514-patient study evaluating the efficacy and safety of SEP-225289 for the treatment of Major ...
|
|
|
Medical News: Sepracor Provides Update On Clinical Trials For SEP-225289 And LUNESTA(R) Pediatrics
Main Category: Depression Also Included In: Clinical Trials / Drug Trials; Pediatrics / Children's Health email to a friend printer friendly view / write opinions rate article Current Article Ratings: Patient / Public: Health Professional:...
|
|
|
Sepracor Provides Update On Clinical Trials For SEP-225289 And LUNESTA(R) Pediatrics
Sepracor Inc.(Nasdaq: SEPR) announced that it has completed the analysis and validation of the preliminary results of a Phase II, 514-patient study evaluating the efficacy and safety of SEP-225289 for the treatment of Major Depressive...
|
|
|
Sepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA Pediatrics
MARLBOROUGH, Mass.Sepracor Inc. (Nasdaq: SEPR) today announced that it has completed the analysis and validation of the preliminary results of a Phase II, 514-patient study evaluating the efficacy and safety of SEP-225289 for the...
|
|
|
Sepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA Pediatrics
- Sepracor Inc.(Nasdaq: SEPR) today announced that it has completed the analysis and validation of the preliminary results of a Phase II, 514-patient study evaluating the efficacy and safety of SEP-225289 for the treatment of Major ...
|
|
|
Sepracor Clinical Depressive Disorder Drug Misses Primary Endpoint In Phase II Trials - Quick Facts
PM ET RELATED NEWS TOP MARKET NEWS (RTTNews) - Wednesday, Sepracor Inc.(SEPR: News ) said its Phase II clinical trail to evaluate efficacy and safety of SEP-225289 for treatment of major depressive disorder did not meet the primary end...
|
|
|
Sepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA Pediatrics
Sepracor Inc.(Nasdaq: SEPR) today announced that it has completed the analysis and validation of the preliminary results of a Phase II, 514-patient study evaluating the efficacy and safety of SEP-225289 for the treatment of Major ...
|
|
|
Sepracor (SEPR) Sinks After SEP-22528 Fails To Meet Endpoint and Two Lunesta Studies Put On Hold
Shares of Sepracor, Inc.(Nasdaq: SEPR) have re-opened and are trading lower after an update on Clinical Trials for SEP-225289 and LUNESTA. Shares are down 16% to $15 per share. Sepracor completed the analysis and validation of the...
|
|
|
Sepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA Pediatrics
MARLBOROUGH, Mass.--(Business Wire)-- Sepracor Inc.(Nasdaq: SEPR) today announced that it has completed the analysis and validation of the preliminary results of a Phase II, 514-patient study evaluating the efficacy and safety of SEP...
|
|
|
Sepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA P
Sepracor Inc.(Nasdaq: SEPR) today announced that it has completed the analysis and validation of the preliminary results of a Phase II, 514-patient study evaluating the efficacy and safety of SEP-225289 for the treatment of Major ...
|
|
|
Sepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA Pediatrics
Companies mentioned in this article: Sepracor Inc.MARLBOROUGH, Mass. -- (BUSINESSWIRE) -- Sepracor Inc. (Nasdaq: SEPR) today announced that it has completed the analysis and validation of the preliminary results of a Phase II, 514...
|
|
|
Sepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA(R) Pediatrics
BusinessWire - Sepracor Inc.(Nasdaq: SEPR) today announced that it has completed the analysis and validation of the preliminary results of a Phase II, 514-patient study evaluating the efficacy and safety of SEP-225289 for the treatment of...
|
|
|
Sepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA(R) Pediatrics
nced that it has completed the analysis and validation of the preliminary results of a Phase II, 514-patient study evaluating the efficacy and safety of SEP-225289 for the treatment of Major Depressive Disorder, including...
|
|
|
Sepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA Pediatrics
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc.(Nasdaq: SEPR - News) today announced that it has completed the analysis and validation of the preliminary results of a Phase II, 514-patient study evaluating the efficacy and safety of...
|
|
|
Sepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA(R) Pediatrics
Sepracor Inc.( NASDAQ:SEPR) today announced that it has completed the analysis and validation of the preliminary results of a Phase II, 514-patient study evaluating the efficacy and safety of SEP-225289 for the treatment of Major ...
|
|
|
Sepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA Pediatrics
Sepracor Inc.(Nasdaq: SEPR) today announced that it has completed the analysis and validation of the preliminary results of a Phase II, 514-patient study evaluating the efficacy and safety of SEP-225289 for the treatment of Major ...
|
|
|
Sepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA(R) Pediatrics
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Sepracor Inc.(Nasdaq: SEPR) today announced that it has completed the analysis and validation of the preliminary results of a Phase II, 514-patient study evaluating the efficacy and safety of SEP...
|
|
|
Sepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA Pediatrics
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc.(Nasdaq: SEPR - News) today announced that it has completed the analysis and validation of the preliminary results of a Phase II, 514-patient study evaluating the efficacy and safety of...
|
|
|
Sepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA Pediatrics
Sepracor Inc.(Nasdaq: SEPR) today announced that it has completed the analysis and validation of the preliminary results of a Phase II, 514-patient study evaluating the efficacy and safety of SEP-225289 for the treatment of Major ...
|
|
|
Sepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA Pediatrics
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc.(Nasdaq: SEPR) today announced that it has completed the analysis and validation of the preliminary results of a Phase II, 514-patient study evaluating the efficacy and safety of SEP...
|
|
|
Major Depressive Disorder in Children and Adolescents After Renal Transplantation
Print Save in My Library Free Abstract Ghanizadeh A et al.- This cross-sectional study evaluated the prevalence of major depressive disorder and depressive symptoms in children and adolescents after renal transplantation. The rate of...
|
|
|
Living With Depressive Symptoms: Patients With Heart Failure
(Click the title below to leave the MDLinx Network and go to the Journal's Website) American Journal of Critical Care, 06/29/09 Print Save in My Library Free Abstract Dekker RL et al.- Patients with heart failure experience symptoms of...
|
